Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, host Sarah Hughan tells all on Orthocell’s (ASX:OCC) nerve repair product deemed safe and effective for use in the surgical repair of peripheral nerves.
A study successfully met all end points, making way for the company to lodge an FDA submission to commercially distribute Remplir™ into a growing US$1.6B market.
Tune in to get the latest.
While Orthocell is a Stockhead advertiser, it did not sponsor this content.